News, Articles & Media

Archive for May, 2015

Keith Hudson joins Caldera Health as Director of Research and Development

NBR notes Dr Keith Hudson’s appointment


Dr Keith Hudson

Monday 18 May 2015
– Prostate cancer diagnostics company, Caldera Health, has appointed Dr Keith Hudson as director of research and development.

Keith holds a PhD in immunology from the University of Auckland (1993) and spent five years conducting postdoctoral research at the University of Oxford then the University of Birmingham. He returned to New Zealand in 1998 and worked for Genesis Research and Development, leading a research programme which resulted in several patent applications and received in excess of NZ $6 million dollars in government funding. As Chief Scientific Officer, Cartesian Group, Keith was also instrumental in developing bioinformatics software that turned genomic DNA information into useable gene sequences using a patented pattern search technology. The initiative was subsequently spu

n out into a US analytical software company.

Read the full NBR article here




Caldera close to global breakthrough on new prostate cancer test, seeks new investors

Jonathan Underhill reports in NBR on Caldera’s work on a gene-sequencing replacement for the world’s most widely used prostate cancer test.

Jim caldera2211030www

Caldera Health founder Jim Watson

Monday 18 May, 2015 – Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, is seeking new investors to complete a $2 million capital raising to finish clinical studies and put the research in front of potential commercial partners.

Auckland-based Caldera has attracted $5.93 million of investment since being incorporated in 2009, made up of $5.4 million from investors including New Image Group founder Graeme Clegg, Stephen Tindall’s K One W One, the government’s NZ Venture Investment Fund, and about $568,000 from Callaghan Innovation and its predecessors. It has raised about $1.1 million of the $2 million sought in its latest offer of 2.5 million shares at 80c apiece. Each share comes with a ‘stapled’ option to buy another share at that price by 2017. Investors need to put in a minimum of $750,000.

Read the full NBR article here

NZ biotech firm makes giant strides in cancer fight

ComputerWorld New Zealand‘s Randal Jackson speaks with Caldera’s Graham Watt and Kristen Chalmet


13 May 2015– A privately owned New Zealand biotech company has made huge progress in developing a replacement for the PSA prostate cancer test.

At present, there are 100 million PSA tests conducted worldwide each year but the test reliability suffers from false negative and false positive results with PSA testing costing global health systems around US$2 billion annually.

Caldera Ltd was established in 2010 as a molecular diagnostic development company. Prostate cancer is its first target, though the current development work has the potential, eventually, to target all cancers.

Breast cancer would be be the next target, says managing director Graham Watt.

Read the full Computerworld New Zealand article here

May 2015 Newsletter to Shareholders

Read the May 2015 Newsletter for news on the following:

  • The appointment of a new Director of Research and Development
  • Our recent project review,
  • The R&D growth grant we received from Callaghan Innovation
  • Migrating our accounting system to the cloud
  • Two further staff appointments.

This newsletter also contains a third article on prostate cancer from Dr Jim Watson.

Offer of Equity Securities in Caldera Health Limited

Caldera is raising capital by way of an offer of Equity Securities in Caldera Health Limited.

The offer is made without disclosure under Part 3 of the Financial Markets Conduct Act 2013, in reliance upon exclusions in clauses 3, 4, and 5 of Schedule 1 to the Act.

Read the Company’s notice sent to the Financial Markets Authority under the Financial Markets Conduct Act 2013  here.